Acute Stroke InterventionNCT06828679
Using AI Systems to Optimize the Clinical Outcome of Stroke Patients
A study testing Acupuncture, Robotic Training and Neuromuscular Electrical Stimulation Group in people with Acute Stroke Intervention and Acute Stroke, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical/occupational therapists in Hong Kong through AI and precision rehabilitation. Read more about this study
- Who is it for?
- Ages 65 to 80 years
- Conditions the study is for
- Acute Stroke Intervention, Acute Stroke, Acute Ischemic Stroke
- What is being tested?
- Acupuncture, Robotic Training and Neuromuscular Electrical Stimulation Group
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Jul 2025to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 80 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
None listed.
Who cannot join
- Unconscious or bed-bound;
- Uncontrollable diabetes;
- Anticipated non-adherence to treatment schedule;
- On cardiac pacemaker;
- Other severe comorbidities (heart/kidney failure, deranged liver function).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
The Chinese University of Hong Kong
Hong Kong, Sha Tin, 852
Yat Sing Kelvin Lau, MSc, 85296363365, yatsingkelvinlau@cuhk.edu.hk
Chi Kwan Vincent Cheung, PhD
About this study
Official title: Personalized Rehabilitation Pathways to Maximal Motor Functional Return Through an AI Recovery Prediction System for Diverse Stroke Survivors
This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical/occupational therapists in Hong Kong through AI and precision rehabilitation. To reduce the socioeconomic burden from the stroke survivors' loss of independence and their care (>HK$15 billion/year), the efficacy of rehabilitation and efficiency of its delivery must be improved. These goals can be achieved by prescribing them with individually tailored rehabilitations predicted to yield maximal functional return. Defining a predictive model for such personalization remains challenging given the immense heterogeneity of stroke. The investigators aim to build an explainable AI system that predicts a subject's recovery potential and the treatment option that may realize this potential based on multi-modal pre-rehab assessments. Data from clinical, neuroimaging, neurophysiological, and multi-omic evaluations will be collected from stroke survivors (N≥400) before they undergo upper limb rehab with usual care, neuromuscular stimulation, robotic training, or acupuncture. Machine learning-extracted data features will be used to train decision-tree and neural-network AI algorithms for robust predictions. As soon as the model is validated, the investigators will deploy it to implement a personalized rehab program in the community. Our model's ability to predict the optimal intervention from a wide spectrum of input modalities distinguishes ours from previous less-than-accurate models. Our interdisciplinary team of 13 PIs with expertise in neurology, PT/OT, acupuncture, electrical/biomed. engineering, robotics, neuroscience, neuroimaging, multi-omics, data science, and clinical trial management will put us in a world-unique position to execute this project successfully and generate opportunities of interdisciplinary education. In the long run, our prediction system will accelerate marketization of new rehab strategies by facilitating their clinical-trial evaluations in more targeted subjects, thereby leading Hong Kong to be a future global hub of innovative rehabilitation.
Read the detailed description
DELIVERABLE 1: Overview of Data Collection Plan. Subacute stroke survivors (N=400) will be recruited and randomly assigned to one of four groups, which will receive usual rehab care only, and usual care plus acupuncture, robotic, or neuromuscular electrical stimulation (NMES) training, respectively. Each subject will be evaluated before (A0), after (A1) and 6 months after the start of intervention (A2). At A0, thorough clinical, neurophysiological (EEG, EMG, TMS), MRI, and blood-based assessments will be made for deriving predictive recovery markers. At A1 and A2, only the clinical scores and EMG will be assessed for characterizing post-rehab functional gain and long-term recovery. Also, in all groups clinical scores will be recorded midway through intervention (A½) to monitor treatment progress. Treatments will last ≥1 month with ≥20 training sessions. All A0, A1, and A2 data will be analyzed offline with machine learning and other methods, and then used to train the AI model, PRAISE-HK (Precision Rehabilitation AI System for Enhancing recovery in Hong Kong and beyond).
DELIVERABLE 2: Explainable AI Models of Recovery. Overview. Our AI system receives high-dimensional data inputs from diverse modalities, each of which requires unique processing techniques tailored to the specific characteristics of the data type for analysis. Neuroimaging data, for instance, demand specialized image processing algorithms for deriving brain structural and functional measures, while time series data such as EEG and EMG must first be analyzed with signal processing tools that capture embedded patterns across varying temporal resolutions. The need for domain-specific preprocessing of diverse data types engenders a level of analytic complexity that defies standard deep learning techniques, which may not accommodate the unique challenges presented by each modality. To obtain actionable, clinically relevant insights while ensuring interpretability and integration of the multimodal data, more sophisticated algorithms beyond standard deep learning are needed.
As such, the investigators propose the construction of a sophisticated AI fusion model as the core of PRAISE-HK. Fusion model is a machine learning approach that integrates input features from multiple data modalities in a way that leverages their unique contributions to make a prediction more accurate and robust than any single modality could produce. Although the number of subjects here (N=400) is, to the best of our knowledge, the highest among all similar studies, for high-dimensional data this number is small enough to impose rather stringent constraints on the choice of analytical methods should overfitting be avoided, and model generalization ensured. With these considerations, the investigators will construct our fusion model in two phases. Phase 1 involves extraction of predictors from the individual modalities through their independent processing with domain-specific AI models. This phase is necessary since each modality can yield the most valuable information only with distinct processing pipelines. Phase 2 involves the fusion of these processed modalities. The investigators will formulate a specialized fusion model that accommodate the relatively small sample size, the predictors' high dimensionality, and potential instances of missing data. The final model will capitalize on the strengths of the domain-specific phase-1 outputs and combine their insights for improved prediction accuracy.
Phase 1: Modality-specific Feature Extractions. For the neuroimaging and multi-omics modalities, the investigators will leverage pre-trained models to map high-dimensional inputs to a reduced set of informative features or embeddings. The investigators will start by fine-tuning foundation models based on each dataset, and then develop modality-specific models using the pre-trained and fine-tuned foundation models as feature extractors. For time-series data such as EMG, EEG, and motion capture data, both standard and custom-derived procedures will be used to filter noise and identify suitable predictors. From the EMG, non-negative matrix factorization and our recently proposed rectified latent variable model will be used to extract muscle synergy indices, which, from our preliminary results (see below), contain predictive stroke recovery information. From the EEG and EMG, coherence between these two signals (cortico- muscular coherence) and that between EEG and muscle synergy activations (cortico-synergy coherence) will be computed through spectral analysis. From the motion capture data, movement parameters such as joint motion range can be extracted with standard methods. All parameters above will be used as predictors in phase 2.
Phase 2: AI Fusion Model. Once the investigators have extracted the predictors from each modality, the investigators will develop a fusion model, one for each treatment group and each clinical score, that integrates these A0 predictor inputs for a prediction of the A1 and A2 scores . Since the investigators do not have prior information on the suitability of the different methods to be used in fusion models, the investigators will evaluate the performance of various models. Artificial neural networks with meta-learning will be used for their capacity to learn from a rich set of data features. Their performance will be benchmarked against other models such as logistic regression, Bayesian methods, and random forests, methods that are advantageous for smaller datasets such as ours. For each treatment group, the fusion model will be trained on the phase-1 predictors with the labelled data from the 100 subjects as inputs to predict the score improvements at A1 and A2.
Realistically, the investigators anticipate that our final database will have occasional missing data points. The investigators will employ mutual information-based imputation techniques to estimate missing heterogenous values, thereby making full use of the available data and preventing biases in model training. Sensitivity analyses will be conducted to assess the impact of the missing data on model predictions, thereby ensuring the reliability of our findings.
Through the entire system construction process, the investigators will utilize and compare different AI algorithms for phase-1 feature extractions and phase-2 fusion. The models and approaches employed will be iteratively refined based on test performance metrics and clinical feedback. Historical data will be utilized to validate the models through retrospective assessment of the effectiveness of the recommended interventions in previous clinical scenarios.
Additional Phase 3: Building Decision-making Framework. For every subject, by comparing the phase-2 outcome predictions across the treatment-specific models, one may already decide on an ideal intervention for the subject simply by selecting the treatment whose model yields the best A2 improvement. But this selection process is not transparent, because the fusion models do not explicitly indicate how the many predictors interact to lead the models to collectively arrive at the recommended treatment. To enhance the AI system's explanability, the investigators will implement a phase 3 for constructing an explicit decision-making framework that guides intervention selection, one analogous to the clinically successful PREP decision-tree algorithm of Stinear et al. A classifier will be trained with the phase-1 predictors and the phase-2 score predictions of all subjects (N=400) serving as inputs, and the ranked intervention preferences inferred from phase-2 outcome comparison as outputs. The trained classifier can serve as a decision support tool that reveals the most parsimonious set of evaluations needed for reaching decisions, and provides transparent reasoning behind its recommendations, thereby enhancing our understanding of why particular subjects are assigned to each treatment. To maximize interpretability, the investigators will implement decision-tree algorithms such as the random forests, which are capable of discerning complex, nonlinear relationships among the variables.
- Being tested
- Acupuncture, control group, Robotic Training, Neuromuscular Electrical Stimulation Group
- Keywords
- stroke, motor neuroscience, MRI, rehabilitation, muscle coordination, electromyography, Artificial intelligence, Transcranial Magnetic Stimulation, neuroimaging, Proteomics, Metabolomics, Genomics, Epigenomics, Acupuncture, biomarkers, muscle synergies
- Medical subject headings
- Stroke, Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcupunctureOther
Patients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) [66]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) [67]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) [68]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation [69] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation [70]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1).
control groupOther
Subjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1).
Robotic TrainingDevice
For this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support [60]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window.
Neuromuscular Electrical Stimulation GroupDevice
For this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts [63]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot.
| Study group | Role | What they receive |
|---|---|---|
| Rehabilitation Control Group | Active comparator | Subacute stroke survivors in this group, patients will receive usual rehab care only. Receives: Other: control group |
| Acupuncture Group | Active comparator | Subacute stroke survivors in this group, patients will receive usual rehab care plus acupuncture Receives: Other: Acupuncture |
| Robotic Training Group | Active comparator | Subacute stroke survivors in this group, patients will receive usual rehab care plus robotic training Receives: Device: Robotic Training |
| NMES Group | Active comparator | Subacute stroke survivors in this group, patients will receive usual rehab care plus Neuromuscular Electrical Stimulation (NMES) Receives: Device: Neuromuscular Electrical Stimulation Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Surface EMG Recordings
Surface EMG electrodes may be conveniently used to record myoelectric activities of multiple muscles during voluntary movement. This data can reveal the muscle coordination patterns utilized by the motor system for control. We have previously shown that muscle synergies, building blocks of muscle coordination decomposed from EMG using machine learning, may serve as markers of post-stroke functional assessment and prognosis. Here, we will record EMG from 16 affected-side muscles during 8-10 activities of daily living.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Kinematic recordings
We will utilize motion capture technology to analyze stroke patients' movements by attaching reflective markers to their bodies. This setup will allow us to record their performance during 8 to 10 activities of daily living. The collected data will enable us to evaluate joint angles and movement patterns, providing insights into functional capabilities and informing rehabilitation strategies.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Cortico-muscular Coherence (CMC) from Electroencephalography (EEG) and EMG
The CMC is a measure, derived from concurrent EEG and EMG during movement, that quantifies the overall capacity of the cortex to coordinate activities of multiple muscles. After stroke, the CMC between different brain regions and muscles are altered. Given that the structural connectome may predict recovery potential, it is likely that CMC should carry some predictive power. We will record EEG (64 channels) during the EMG assessment described above. The CMC between each EEG channel and each muscle may serve as inputs to the prediction system.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Secondary outcomes (6)
Fugl-Meyer Assessment for Upper Extremity
The Fugl-Meyer Assessment (FMA) for Upper Extremity is a standardized test used to evaluate motor function, sensation, and joint function in individuals with neurological conditions, particularly after a stroke. It assesses voluntary movements of the shoulder, elbow, wrist, and fingers, as well as sensory capabilities. Scoring ranges from 0 (no function) to 66 (full function), helping to identify impairments and monitor recovery progress in rehabilitation settings.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Modified Tardieu Scale
The Modified Tardieu Scale is a clinical tool used to assess spasticity in individuals with neurological conditions. It measures the resistance of a muscle to passive stretch at different velocities, providing insights into the severity of spasticity. The scale includes observations of muscle reaction during slow and fast stretches, rating the response from 0 (no resistance) to 4 (very strong resistance). This assessment helps guide treatment and rehabilitation strategies for managing spasticity.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
National Institutes of Health Stroke Scale
The National Institutes of Health Stroke Scale (NIHSS) is a clinical assessment tool used to evaluate the severity of stroke symptoms. It consists of 15 items that assess functions such as consciousness, vision, movement, speech, and sensation. Each item is scored, with higher total scores indicating more severe impairment. The NIHSS is essential for diagnosing stroke, guiding treatment decisions, and predicting patient outcomes.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Brunnstrom Stages
The Brunnstrom Stages are a framework for understanding the progression of motor recovery after a stroke. Developed by Signe Brunnstrom, the stages range from 1 to 7, describing the evolution from flaccidity (Stage 1) to the re-emergence of coordinated movement and normal function (Stage 7). Each stage reflects specific patterns of muscle tone and voluntary movement, helping clinicians plan rehabilitation strategies and track recovery progress.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Wolf Motor Function Test
The Wolf Motor Function Test (WMFT) is a standardized assessment used to evaluate upper extremity motor function in individuals after a stroke or neurological injury. It measures the speed and quality of performing various tasks involving hand and arm movements, such as reaching, grasping, and manipulation. The test includes timed tasks and a functional score, providing insights into motor recovery and guiding rehabilitation interventions.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Barthel Index
The Barthel Index is a measure of an individual's ability to perform activities of daily living (ADLs) independently. It assesses ten specific tasks, including feeding, bathing, dressing, and mobility, assigning scores that reflect the level of assistance required. The total score ranges from 0 (completely dependent) to 100 (fully independent), making it a valuable tool for evaluating functional status and progress in rehabilitation, particularly after stroke or other disabilities.
Measured: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2025
- Study start1 Jul 2025
- Primary completion31 Dec 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Stroke InterventionStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Collaborators
- The Hong Kong Polytechnic University, City University of Hong Kong, Hong Kong Baptist University, The University of Western Australia
- Responsible party
- Principal investigator, Cheung Chi Kwan Vincent, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06828679
- Sponsor's protocol ID
- STG-001
- Other IDs
- STG1/M-401/24-N
- Status last verified
- Dec 2025
- First submitted
- 13 Dec 2024
- Last updated
- 22 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personalized Rehabilitation Pathways to Maximal Motor Functional Return Through an AI Recovery Prediction System for Diverse Stroke Survivors
- ClinicalTrials.gov ID
- NCT06828679
- Acronym / sponsor ID
- STG-001
- Keywords
- stroke, motor neuroscience, MRI, rehabilitation, muscle coordination, electromyography, Artificial intelligence, Transcranial Magnetic Stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Collaborators
- The Hong Kong Polytechnic University, City University of Hong Kong, Hong Kong Baptist University, The University of Western Australia
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 14 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical/occupational therapists in Hong Kong through AI and precision rehabilitation. To reduce the socioeconomic burden from the stroke survivors' loss of independence and their care (>HK$15 billion/year), the efficacy of rehabilitation and efficiency of its delivery must be improved. These goals can be achieved by prescribing them with individually tailored rehabilitations predicted to yield maximal functional return. Defining a predictive model for such personalization remains challenging given the immense heterogeneity of stroke. The investigators aim to build an explainable AI system that predicts a subject's recovery potential and the treatment option that may realize this potential based on multi-modal pre-rehab assessments. Data from clinical, neuroimaging, neurophysiological, and multi-omic evaluations will be collected from stroke survivors (N≥400) before they undergo upper limb rehab with usual care, neuromuscular stimulation, robotic training, or acupuncture. Machine learning-extracted data features will be used to train decision-tree and neural-network AI algorithms for robust predictions. As soon as the model is validated, the investigators will deploy it to implement a personalized rehab program in the community. Our model's ability to predict the optimal intervention from a wide spectrum of input modalities distinguishes ours from previous less-than-accurate models. Our interdisciplinary team of 13 PIs with expertise in neurology, PT/OT, acupuncture, electrical/biomed. engineering, robotics, neuroscience, neuroimaging, multi-omics, data science, and clinical trial management will put us in a world-unique position to execute this project successfully and generate opportunities of interdisciplinary education. In the long run, our prediction system will accelerate marketization of new rehab strategies by facilitating their clinical-trial evaluations in more targeted subjects, thereby leading Hong Kong to be a future global hub of innovative rehabilitation.
Detailed description
DELIVERABLE 1: Overview of Data Collection Plan. Subacute stroke survivors (N=400) will be recruited and randomly assigned to one of four groups, which will receive usual rehab care only, and usual care plus acupuncture, robotic, or neuromuscular electrical stimulation (NMES) training, respectively. Each subject will be evaluated before (A0), after (A1) and 6 months after the start of intervention (A2). At A0, thorough clinical, neurophysiological (EEG, EMG, TMS), MRI, and blood-based assessments will be made for deriving predictive recovery markers. At A1 and A2, only the clinical scores and EMG will be assessed for characterizing post-rehab functional gain and long-term recovery. Also, in all groups clinical scores will be recorded midway through intervention (A½) to monitor treatment progress. Treatments will last ≥1 month with ≥20 training sessions. All A0, A1, and A2 data will be analyzed offline with machine learning and other methods, and then used to train the AI model, PRAISE-HK (Precision Rehabilitation AI System for Enhancing recovery in Hong Kong and beyond).
DELIVERABLE 2: Explainable AI Models of Recovery. Overview. Our AI system receives high-dimensional data inputs from diverse modalities, each of which requires unique processing techniques tailored to the specific characteristics of the data type for analysis. Neuroimaging data, for instance, demand specialized image processing algorithms for deriving brain structural and functional measures, while time series data such as EEG and EMG must first be analyzed with signal processing tools that capture embedded patterns across varying temporal resolutions. The need for domain-specific preprocessing of diverse data types engenders a level of analytic complexity that defies standard deep learning techniques, which may not accommodate the unique challenges presented by each modality. To obtain actionable, clinically relevant insights while ensuring interpretability and integration of the multimodal data, more sophisticated algorithms beyond standard deep learning are needed.
As such, the investigators propose the construction of a sophisticated AI fusion model as the core of PRAISE-HK. Fusion model is a machine learning approach that integrates input features from multiple data modalities in a way that leverages their unique contributions to make a prediction more accurate and robust than any single modality could produce. Although the number of subjects here (N=400) is, to the best of our knowledge, the highest among all similar studies, for high-dimensional data this number is small enough to impose rather stringent constraints on the choice of analytical methods should overfitting be avoided, and model generalization ensured. With these considerations, the investigators will construct our fusion model in two phases. Phase 1 involves extraction of predictors from the individual modalities through their independent processing with domain-specific AI models. This phase is necessary since each modality can yield the most valuable information only with distinct processing pipelines. Phase 2 involves the fusion of these processed modalities. The investigators will formulate a specialized fusion model that accommodate the relatively small sample size, the predictors' high dimensionality, and potential instances of missing data. The final model will capitalize on the strengths of the domain-specific phase-1 outputs and combine their insights for improved prediction accuracy.
Phase 1: Modality-specific Feature Extractions. For the neuroimaging and multi-omics modalities, the investigators will leverage pre-trained models to map high-dimensional inputs to a reduced set of informative features or embeddings. The investigators will start by fine-tuning foundation models based on each dataset, and then develop modality-specific models using the pre-trained and fine-tuned foundation models as feature extractors. For time-series data such as EMG, EEG, and motion capture data, both standard and custom-derived procedures will be used to filter noise and identify suitable predictors. From the EMG, non-negative matrix factorization and our recently proposed rectified latent variable model will be used to extract muscle synergy indices, which, from our preliminary results (see below), contain predictive stroke recovery information. From the EEG and EMG, coherence between these two signals (cortico- muscular coherence) and that between EEG and muscle synergy activations (cortico-synergy coherence) will be computed through spectral analysis. From the motion capture data, movement parameters such as joint motion range can be extracted with standard methods. All parameters above will be used as predictors in phase 2.
Phase 2: AI Fusion Model. Once the investigators have extracted the predictors from each modality, the investigators will develop a fusion model, one for each treatment group and each clinical score, that integrates these A0 predictor inputs for a prediction of the A1 and A2 scores . Since the investigators do not have prior information on the suitability of the different methods to be used in fusion models, the investigators will evaluate the performance of various models. Artificial neural networks with meta-learning will be used for their capacity to learn from a rich set of data features. Their performance will be benchmarked against other models such as logistic regression, Bayesian methods, and random forests, methods that are advantageous for smaller datasets such as ours. For each treatment group, the fusion model will be trained on the phase-1 predictors with the labelled data from the 100 subjects as inputs to predict the score improvements at A1 and A2.
Realistically, the investigators anticipate that our final database will have occasional missing data points. The investigators will employ mutual information-based imputation techniques to estimate missing heterogenous values, thereby making full use of the available data and preventing biases in model training. Sensitivity analyses will be conducted to assess the impact of the missing data on model predictions, thereby ensuring the reliability of our findings.
Through the entire system construction process, the investigators will utilize and compare different AI algorithms for phase-1 feature extractions and phase-2 fusion. The models and approaches employed will be iteratively refined based on test performance metrics and clinical feedback. Historical data will be utilized to validate the models through retrospective assessment of the effectiveness of the recommended interventions in previous clinical scenarios.
Additional Phase 3: Building Decision-making Framework. For every subject, by comparing the phase-2 outcome predictions across the treatment-specific models, one may already decide on an ideal intervention for the subject simply by selecting the treatment whose model yields the best A2 improvement. But this selection process is not transparent, because the fusion models do not explicitly indicate how the many predictors interact to lead the models to collectively arrive at the recommended treatment. To enhance the AI system's explanability, the investigators will implement a phase 3 for constructing an explicit decision-making framework that guides intervention selection, one analogous to the clinically successful PREP decision-tree algorithm of Stinear et al. A classifier will be trained with the phase-1 predictors and the phase-2 score predictions of all subjects (N=400) serving as inputs, and the ranked intervention preferences inferred from phase-2 outcome comparison as outputs. The trained classifier can serve as a decision support tool that reveals the most parsimonious set of evaluations needed for reaching decisions, and provides transparent reasoning behind its recommendations, thereby enhancing our understanding of why particular subjects are assigned to each treatment. To maximize interpretability, the investigators will implement decision-tree algorithms such as the random forests, which are capable of discerning complex, nonlinear relationships among the variables.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Rehabilitation Control Group | Active comparator | Other: control groupSubacute stroke survivors in this group, patients will receive usual rehab care only. |
| Acupuncture Group | Active comparator | Other: AcupunctureSubacute stroke survivors in this group, patients will receive usual rehab care plus acupuncture |
| Robotic Training Group | Active comparator | Device: Robotic TrainingSubacute stroke survivors in this group, patients will receive usual rehab care plus robotic training |
| NMES Group | Active comparator | Device: Neuromuscular Electrical Stimulation GroupSubacute stroke survivors in this group, patients will receive usual rehab care plus Neuromuscular Electrical Stimulation (NMES) |
Who may qualify
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (5 listed)
- Unconscious or bed-bound;
- Uncontrollable diabetes;
- Anticipated non-adherence to treatment schedule;
- On cardiac pacemaker;
- Other severe comorbidities (heart/kidney failure, deranged liver function).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AcupuncturePatients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) [66]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) [67]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) [68]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation [69] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation [70]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1). | Other | Acupuncture Group |
| control groupSubjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1). | Other | Rehabilitation Control Group |
| Robotic TrainingFor this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support [60]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window. | Device | Robotic Training Group |
| Neuromuscular Electrical Stimulation GroupFor this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts [63]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot. | Device | NMES Group |
Primary outcome
Surface EMG Recordings
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Surface EMG electrodes may be conveniently used to record myoelectric activities of multiple muscles during voluntary movement. This data can reveal the muscle coordination patterns utilized by the motor system for control. We have previously shown that muscle synergies, building blocks of muscle coordination decomposed from EMG using machine learning, may serve as markers of post-stroke functional assessment and prognosis. Here, we will record EMG from 16 affected-side muscles during 8-10 activities of daily living.
Kinematic recordings
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
We will utilize motion capture technology to analyze stroke patients' movements by attaching reflective markers to their bodies. This setup will allow us to record their performance during 8 to 10 activities of daily living. The collected data will enable us to evaluate joint angles and movement patterns, providing insights into functional capabilities and informing rehabilitation strategies.
Cortico-muscular Coherence (CMC) from Electroencephalography (EEG) and EMG
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
The CMC is a measure, derived from concurrent EEG and EMG during movement, that quantifies the overall capacity of the cortex to coordinate activities of multiple muscles. After stroke, the CMC between different brain regions and muscles are altered. Given that the structural connectome may predict recovery potential, it is likely that CMC should carry some predictive power. We will record EEG (64 channels) during the EMG assessment described above. The CMC between each EEG channel and each muscle may serve as inputs to the prediction system.
6 secondary outcomes
Fugl-Meyer Assessment for Upper Extremity
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Modified Tardieu Scale
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
National Institutes of Health Stroke Scale
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Brunnstrom Stages
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Wolf Motor Function Test
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Barthel Index
Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2025.
- Individual participant dataSharing planned: Yes
Related trials for Acute Stroke Intervention
Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
Acute Ischemic Stroke
Recruiting
Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)
Stroke, Acute, Stroke
Recruiting
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring
Acute Ischemic Stroke, Cerebral Autoregulation
Recruiting
A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke
Acute Ischemic Stroke Patients, Large Vessel Occlusion
RecruitingObservational study
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
Stroke, Stroke, Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acupuncture, Robotic Training and Neuromuscular Electrical Stimulation Group in people with Acute Stroke Intervention and Acute Stroke, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yat Sing Kelvin Lau, MSc (85296363365, yatsingkelvinlau@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surface EMG Recordings (time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.